

sidering and rejecting a more paternalistic approach, they suggest that the patient should receive a description of the nonstandard portion of the treatment and its risks, benefits, and alternatives, as well as all available data and information about conflicts of interest. These constitute most of the requirements in the Common Rule on research consent, but confidentiality, compensation for harms incurred, and voluntariness of participation are left out. It is hard to imagine opposition to adding those points. The authors also allude to the “reasonable patient” standard that is often used in discussions of consent in the clinical practice setting. They seem to have dealt with the in-between case of innovative therapy by combining the disclosure requirements for research and clinical practice. Only oversight of the consent process by the institutional review board is left out, and that may be one of the appropriate tasks for the oversight mechanism that the authors suggest. It is not clear what would be gained if their new guidelines were adopted.

Eaton and Kennedy are surely right that we need to explicitly recognize the in-between category of innovative research. They have also raised the right questions about that category. But more discussion is needed about how to deal with the questions they pose.

Baruch A. Brody, Ph.D.

Baylor College of Medicine
Houston, TX 77030

Book Reviews Copyright © 2007 Massachusetts Medical Society.

CORRECTIONS

Burch Colposuspension versus Fascial Sling to Reduce Urinary Stress Incontinence (May 24, 2007;356:2143-55). In Figure 1B (page 2145), the muscle label should have read “Rectus abdominus muscle” rather than “Rectus femoris muscle.” We regret the error. The figure has been corrected on the *Journal's* Web site at www.nejm.org.

New York to Trans Fats: You're Out! (May 17, 2007;356:2017-21). The entry for 1985 on the timeline (page 2018) should have read “FDA-commissioned report concludes that artificial trans fats affect serum cholesterol levels similarly to the monosaturated fat oleic acid” rather than “FDA-commissioned report concludes trans fats and saturated fats affect cholesterol similarly.” The timeline has been corrected on the *Journal's* Web site at www.nejm.org.

JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis (February 1, 2007;356:459-68). In Figure 1 (page 462), the DNA-sequence trace for Erythropoietin-Independent Colony for K539L (Patient 5) was incorrect. The figure has been corrected on the *Journal's* Web site at www.nejm.org.

NOTICES

Notices submitted for publication should contain a mailing address and telephone number of a contact person or department. We regret that we are unable to publish all notices received. Notices also appear on the *Journal's* Web site (www.nejm.org/meetings). The listings can be viewed in their entirety or searched by location, month, or key word.

TOXICOLOGY FOR CLINICIANS

The conference will be held in Chicago, Nov. 7 and 8. Contact Contemporary Forums, 11900 Silvergate Dr., Dublin, CA 94568; or call (800) 377-7707; or e-mail info@cfforums.com; or see <http://www.contemporaryforums.com>.

38TH UNION WORLD CONFERENCE ON LUNG HEALTH

The conference, entitled “Confronting the Challenges of HIV and MDR in TB Control and Care,” will be held in Cape Town, South Africa, Nov. 8–12.

Contact the International Union Against Tuberculosis and Lung Disease, 68, boulevard Saint-Michel, 75006 Paris, France; or call (33) 1 44 32 03 60; or fax (33) 1 53 10 85 54; or e-mail capetown2007@iuatld.org; or see <http://www.worldlunghealth.org>.

POLISH ACADEMY OF SCIENCES

A conference entitled “The Advancement of Science and the Dilemma of Dual Use: Why We Can't Afford to Fail” will be held in Warsaw, Poland, Nov. 9 and 10.

Contact the Polish Academy of Sciences, PKiN, POB 24, 00901 Warsaw, Poland; or call (48) 22 6204970; or fax (48) 22 6204910; or see <http://www.pan.pl/english>.

ENDOSCOPIC ULTRASONOGRAPHY LIVE 2007

The course will be offered in Boston, Nov. 9–11.

Contact Judy Aukstikalnis, Harvard Medical School Department of Continuing Education, Harvard MED-CME, P.O. Box 825, Boston, MA 02117-0825; or call (617) 724-3714; or e-mail jaukstikalnis@partners.org; or see <http://www.cme.hms.harvard.edu/courses/endoscopic2007>.

TOPICS IN INTERNAL MEDICINE

The conference will be held in Mystic, CT, Oct. 12–14. It is sponsored by Lahey Clinic.

Contact Office of CME, Lahey Clinic, 41 Mall Rd., Burlington, MA 01805; or call (781) 444-8969; or fax (781) 744-2930; or see <http://www.lahey.org/cme/>.

BELGIAN MENOPAUSE SOCIETY

A conference entitled “Menopausal Side Effects of Systemic Breast Cancer Therapies: An Update on Chemotherapy, Tamoxifen, and AIs” will be held in Brussels on Oct. 13.

Contact Judith Van Cauwenberghe, CHU Saint-Pierre, Hoogstraat 322, 1000 Brussels, Belgium; or call (32) 2 535 43 29; or e-mail judith_vancauwenberghe@stpierre-bru.be; or see <http://www.menopausesociety.be>.

ACADEMY OF MEDICAL-SURGICAL NURSES

The “AMSN 16th Annual Convention” will be held in Las Vegas, Oct. 24–29.

Contact AMSN National Office, E. Holly Ave., Box 56, Pitman, NJ 08071; or call (866) 877-2676; or fax (856) 218-0557; or e-mail amsn@ajj.com; or see <http://www.medsurgnurse.org>.